ARTICLE | Company News
Immuneering, Teva deal
August 10, 2015 7:00 AM UTC
Teva will acquire a 51% stake in Immuneering for $45 million. Immuneering analyzes genomic and proteomic data to generate hypotheses and design follow-up studies for compounds in development. Teva wil...